Status:
COMPLETED
Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Impotence
Eligibility:
MALE
18-65 years
Phase:
PHASE4
Brief Summary
The study objective is to: 1. To evaluate the effect of sildenafil citrate versus placebo on the IIEF\_EF Domain at the end of the double-blind phase 2. To assess the relationship between treatment w...
Eligibility Criteria
Inclusion
- Male subjects aged 18-65.
- Documented clinical diagnosis of erectile dysfunction confirmed by an IIEF-EF Domain score of less than or equal to 25. (If the subject scores greater than 25 on the IIEF-EF Domain, screening procedures should be terminated.)
Exclusion
- Subjects who have been treated with more than 6 doses of sildenafil citrate or any other phosphodiesterase type 5 (PDE-5) inhibitor such as vardenafil or tadalafil for erectile dysfunction \[Note: subjects should not have taken any PDE-5 inhibitors within 4 weeks prior to the date of screening\].
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT00245258
Start Date
November 1 2005
End Date
September 1 2006
Last Update
February 1 2021
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Moscow, Russia, 105425
2
Pfizer Investigational Site
Moscow, Russia, 117036
3
Pfizer Investigational Site
Moscow, Russia, 125101
4
Pfizer Investigational Site
Rostov-on-Don, Russia, 344022